Kansas City, Kan- Riayn Azzouz, living with Duchenne muscular dystrophy (DMD), is participating in a groundbreaking clinical trial at the University of Kansas Health System. The trial involves a one-time injection of a new medication into his heart to improve heart function.
The trial, led by Dr. Pradeep Mammen and Dr. Jeffrey Statland, aims to monitor Ryan's progress over five years.
Riayn Azzouz, patient
- Ryan is participating in his second clinical trial for DMD, which involves a one-time injection of a new medication into his heart.
- He shares his wish to help push science forward and improve the lives of others with DMD.
Renee Azzouz, mom
- Renee expresses her gratitude for the support and opportunities provided by the clinical trials.
- She shares their hopes for the future of DMD research and the importance of continued funding.
Dr. Pradeep Mammen, Heart Failure and Transplantation Cardiologist, The University of Kansas Health System
- Dr. Mammen acknowledges the community's role in pushing for research funding and the importance of embracing novel therapies.
- He explains the trial's details, including the injection process and the monitoring period.
Dr. Jeffrey Statland, Neurologist, The University of Kansas Health System
- Dr. Statland highlights the advancements in genetic and robotic technologies that are improving treatment options.
- He discusses how clinical trials often lead to new treatments.
